Age does not limit the efficacy of ivabradine in patients with chronic heart failure and systolic dysfunction.1
for worsening heart failure (primary end point) by age group
1. Tavazzi L, et al. Eur J Heart Fail. 2013;15(11):1296-1303.you want to know more …
on the analysis of SHIfT AGE
Age does not limit the appropriate use of ivabradine in patients with chronic heart failure and systolic dysfunction.
The effects of ivabradine on cardiovascular outcomes, changes in heart rate, and adverse events, particularly bradycardia, were evaluated according to age group in a recent analysis from SHIFT. Age distribution was divided by quartiles to give four groups (<53 years, n=1522; 53 to <60 years, n=1521; 60 to <69 years, n=1750; and ≥69 years, n=1712). A subgroup (602 patients) underwent 24-h ambulatory ECG Holter monitoring. The relative risk of the primary end point (cardiovascular death or hospitalization for worsening heart failure) was reduced by ivabradine in all age groups, ranging from 38% (hazard ratio 0.62, 95% confidence interval [CI] 0.50-0.78, P <0.001) in the youngest patients <53 years to 16% (hazard ratio 0.84, 95% CI 0.71-0.99, P=0.035) in the oldest patients ≥69 years. Ivabradine uptitration reduced heart rate similarly in all age groups, by 11 bpm. As anticipated, bradycardia and phosphenes occurred more frequently with ivabradine, at a similar rate whatever the age. In the Holter substudy, there were no episodes of severe bradycardia and no clinically relevant pauses with ivabradine in any age group. Age does not limit the appropriate use of ivabradine in patients with chronic heart failure and systolic dysfunction. The safety and efficacy of ivabradine are comparable across all age groups.1